Icon Group is pleased to announce an agreement with ImpediMed Limited (ASX.IPD) for the roll out of 13 SOZO units to establish lymphoedema screening services for breast cancer patients across Australia and New Zealand. These initial units are scheduled to be installed over the balance of the quarter.
SOZO facilitates the identification of each patient’s individual risk of developing lymphoedema, ensuring early detection and the delivery of appropriate education and management to reduce progression. The 13 SOZO units will be implemented across Icon’s cancer centres in Queensland, New South Wales, Victoria, Australian Capital Territory, Tasmania, and Wellington in New Zealand.
“Through the implementation of lymphoedema screening Icon is helping patients take control from the very start of their cancer journey. At a time when there are so many uncertainties for a patient, this service arms them with important knowledge to manage their wellbeing throughout surgery, treatment and beyond,” said Mark Middleton, Icon Group CEO.
SOZO, as a digitally connected health platform, gives ImpediMed the ability to see patient testing in real-time, anywhere in the world. This real-time insight allows ImpediMed to tailor its approach by better managing and reallocating resources when opportunities arise, continuing to evolve services, foster long-term business relationships and help deliver the best possible care.
“We are proud to work with providers like Icon who strive for the highest levels of care for cancer patients and survivors. This agreement opens the door to thousands of patients to participate in a state-of-the-art lymphoedema prevention program aimed at stopping chronic lymphoedema before it starts,” said Richard Carreon, Managing Director and CEO of ImpediMed.